Clinical Trial Update: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment [Phase 1]

View source ↗

Summary

The Phase 1 study evaluating the safety of relatlimab in combination with ipilimumab in advanced melanoma patients who progressed on anti-PD-1 therapy has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 1 | Status: TERMINATED